Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
暂无分享,去创建一个
A. Paci | G. Vassal | L. Nguyen | M. Riggi | R. Ladenstein | P. Brock | G. Veal | D. Valteau‐Couanet | M. Amiel